Wave Life Sciences schedules Singapore court hearing for US redomiciliation

Wave Life Sciences Ltd. (NASDAQ: WVE) has scheduled a Singapore High Court hearing for July 14, 2026, to seek approval of a scheme of arrangement that would redomicile the company from Singapore to the United States as a Delaware corporation.

According to a press release, Wave filed its application with the High Court of the Republic of Singapore on July 1, 2026, under case HC/SUM 2058/2026 in HC/OA 434/2026. The hearing is set for 2:30 p.m. Singapore Time at Chamber 2A of the Supreme Court of Singapore.

The court directed that any affidavits in response to the application be submitted by 4:00 p.m. Singapore Time on July 8, 2026, and that written submissions and bundles of authorities be filed by 4:00 p.m. Singapore Time on July 10, 2026.

Wave previously obtained the required shareholder approval for the redomiciliation. Singapore court approval remains an outstanding condition before the transaction can be completed.

Wave Life Sciences is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, with a pipeline that includes programs in obesity, alpha-1 antitrypsin deficiency, and liver disease, among others.

You May Also Be Interested In

• Royale Energy files 2025 annual report, eyes return to OTCQB
• China SXT Pharmaceuticals launches $9M registered direct offering
• Workday Adaptive Planning wins FedRAMP Moderate authorization